iRhythm Technologies, Inc. (NASDAQ:IRTC) Expected to Post Quarterly Sales of $99.25 Million

Brokerages predict that iRhythm Technologies, Inc. (NASDAQ:IRTCGet Rating) will post $99.25 million in sales for the current quarter, Zacks Investment Research reports. Five analysts have provided estimates for iRhythm Technologies’ earnings. The lowest sales estimate is $96.24 million and the highest is $100.73 million. iRhythm Technologies posted sales of $81.28 million during the same quarter last year, which would indicate a positive year over year growth rate of 22.1%. The company is expected to issue its next quarterly earnings report on Monday, January 1st.

On average, analysts expect that iRhythm Technologies will report full-year sales of $420.09 million for the current financial year, with estimates ranging from $418.26 million to $424.34 million. For the next financial year, analysts expect that the business will report sales of $518.03 million, with estimates ranging from $496.68 million to $542.61 million. Zacks Investment Research’s sales calculations are an average based on a survey of research firms that cover iRhythm Technologies.

iRhythm Technologies (NASDAQ:IRTCGet Rating) last released its quarterly earnings data on Thursday, May 5th. The company reported ($0.80) earnings per share for the quarter, topping the consensus estimate of ($1.06) by $0.26. The business had revenue of $92.40 million during the quarter, compared to analyst estimates of $86.76 million. iRhythm Technologies had a negative return on equity of 34.55% and a negative net margin of 36.43%. The company’s revenue was up 24.4% compared to the same quarter last year. During the same period last year, the company posted ($0.95) EPS.

Several research firms have weighed in on IRTC. Zacks Investment Research lowered iRhythm Technologies from a “buy” rating to a “hold” rating in a report on Wednesday, May 11th. Wolfe Research began coverage on iRhythm Technologies in a report on Tuesday, April 5th. They set an “underperform” rating and a $105.00 price objective on the stock. Citigroup lifted their price objective on iRhythm Technologies from $175.00 to $180.00 in a report on Friday, May 6th. Morgan Stanley decreased their price objective on iRhythm Technologies from $167.00 to $151.00 and set an “overweight” rating on the stock in a report on Thursday, February 24th. Finally, StockNews.com began coverage on iRhythm Technologies in a report on Thursday, March 31st. They set a “sell” rating on the stock. Two investment analysts have rated the stock with a sell rating, two have given a hold rating and nine have given a buy rating to the company’s stock. According to MarketBeat, iRhythm Technologies presently has a consensus rating of “Buy” and a consensus target price of $155.50.

IRTC opened at $132.99 on Friday. The stock has a market cap of $3.96 billion, a price-to-earnings ratio of -31.59 and a beta of 1.24. iRhythm Technologies has a 1 year low of $41.66 and a 1 year high of $169.54. The company has a current ratio of 4.63, a quick ratio of 4.43 and a debt-to-equity ratio of 0.14. The stock has a fifty day moving average price of $138.34 and a 200 day moving average price of $123.68.

In related news, CFO Douglas Devine sold 576 shares of the company’s stock in a transaction on Friday, March 4th. The shares were sold at an average price of $132.67, for a total value of $76,417.92. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link. Also, insider David A. Vort sold 3,161 shares of the company’s stock in a transaction on Friday, March 4th. The shares were sold at an average price of $132.67, for a total transaction of $419,369.87. The disclosure for this sale can be found here. Insiders have sold a total of 11,883 shares of company stock valued at $1,576,518 in the last quarter. Corporate insiders own 1.64% of the company’s stock.

Institutional investors and hedge funds have recently added to or reduced their stakes in the stock. FNY Investment Advisers LLC bought a new stake in shares of iRhythm Technologies in the 1st quarter valued at $55,000. Rockefeller Capital Management L.P. increased its position in shares of iRhythm Technologies by 625.7% in the 3rd quarter. Rockefeller Capital Management L.P. now owns 537 shares of the company’s stock valued at $30,000 after buying an additional 463 shares in the last quarter. Parallel Advisors LLC increased its position in shares of iRhythm Technologies by 380.9% in the 4th quarter. Parallel Advisors LLC now owns 630 shares of the company’s stock valued at $74,000 after buying an additional 499 shares in the last quarter. Nisa Investment Advisors LLC increased its position in shares of iRhythm Technologies by 211.6% in the 4th quarter. Nisa Investment Advisors LLC now owns 1,103 shares of the company’s stock valued at $138,000 after buying an additional 749 shares in the last quarter. Finally, CIBC Asset Management Inc acquired a new position in iRhythm Technologies in the 1st quarter worth $216,000. Institutional investors and hedge funds own 97.92% of the company’s stock.

About iRhythm Technologies (Get Rating)

iRhythm Technologies, Inc, a digital healthcare company, provides ambulatory electrocardiogram (ECG) monitoring products for patients at risk for arrhythmias in the United States. It offers Zio service, an ambulatory cardiac monitoring solution that combines a wire-free, patch-based, and wearable biosensor with a cloud-based data analytic platform to help physicians to monitor patients and diagnose arrhythmias.

Featured Articles

Get a free copy of the Zacks research report on iRhythm Technologies (IRTC)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for iRhythm Technologies (NASDAQ:IRTC)

Receive News & Ratings for iRhythm Technologies Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for iRhythm Technologies and related companies with MarketBeat.com's FREE daily email newsletter.